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esponsibility of InstAbstract Inﬂuenza is one of the most common infections threatening public health worldwide and is
caused by the inﬂuenza virus. Rapid emergence of drug resistance has led to an urgent need to develop
new anti-inﬂuenza inhibitors. In this study we established a 293T cell line that constitutively synthesizes a
virus-based negative strand RNA, which expresses Gaussia luciferase upon inﬂuenza A virus infection.
Using this cell line, an assay was developed and optimized to search for inhibitors of inﬂuenza virus
replication. Biochemical studies and statistical analyses presented herein demonstrate the sensitivity and
reproducibility of the assay in a high-throughput format (Z0 factor value40.8). A pilot screening provides
further evidence for validation of the assay. Taken together, this work provides a simple, convenient, and
reliable HTS assay to identify compounds with anti-inﬂuenza activity.
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Q. Gao et al.3021. Introduction
Inﬂuenza viruses are members of the family of Orthomyxoviridae
and are classiﬁed into three types: inﬂuenza A, B and C viruses
based on antigenic differences. Inﬂuenza A virus has caused
signiﬁcant morbidity in the last and in this century1. To date,
inﬂuenza-speciﬁc drugs include M2 ion channel blockers (aman-
tadine and rimantadine) and neuraminidase inhibitors (oseltamivir
and zanamivir), both of which were approved to prevent and treat
inﬂuenza2. However, rapid emergence of drug-resistant mutants
restricts their utilization3,4, and therefore leads to an urgent need to
develop novel antivirals.
The use of high-throughput screening (HTS) technology for
antiviral discovery is a fairly recent endeavor. Utilizing virus-
inducible reporter genes to quantitate the infectivity has been
achieved for several viruses5,6. A reporter system mimicking the
process of transcription/replication of inﬂuenza virus was con-
structed by Lutz et al.7. Cells were transfected with a reporter
system that expressed Fireﬂy luciferase in a response proportional
to the infectivity of inﬂuenza virus. This luciferase assay is more
rapid and simple than the standard plaque assays. Afterward de
Vries et al.8 adapted this system by substituting Gaussia luciferase.
Gaussia luciferase (hereafter referred to as Gluc), discovered from
the marine copepod Gaussia princeps, can give high levels of light
emission centered at 470 nm by catalyzing the oxidation of the
substrate coelenterazine to coelenteramide9. This reaction requires
no cofactors but O2, and it generates over 100-fold higher
bioluminescent signal intensity when compared with other fre-
quently used luciferase reactions (e.g., Renilla or Fireﬂy lucifer-
ase)10,11. With the help of a secretory signal, Gluc was secreted
into the culture medium. Lysis of the cells was not necessary, and
the measurement of luciferase activity was simple and time-saving,
making Gluc assays a promising technique. Nevertheless, transient
transfection of the Gluc reporter system is likely to introduce
variation between the experiments.
In this work, a stable cell line derived from 293T cell was
established, named 293T-Gluc. It synthesizes the reporter protein
Gluc when infected with inﬂuenza A virus. We then developed a
reporter assay based on this engineered cell line. Antiviral
activities of three anti-inﬂuenza compounds (ribavirin, amantadine
hydrochloride and nucleozin) were assessed by this assay. Results
demonstrated the ability of this assay to identify inﬂuenza
inhibitors. Several parameters (Z0 factor, CV, S/B, S/N) utilized
to evaluate the quality of HTS (high-throughput screening) assays
also validated our approach. These ﬁndings suggest that this
cell-based assay is a promising tool to identify new anti-inﬂuenza
drugs.2. Materials and methods
2.1. Cells and viruses
MDCK and 293T cells were maintained in Dulbecco's modiﬁed
Eagle's medium with 10% (v/v) fetal bovine serum (FBS; Invitro-
gen). The cells were cultured at 37 1C in a humidiﬁed atmosphere
of 5% CO2. Inﬂuenza A/WSN/33 (H1N1) was rescued from eight
plasmids using cocultured MDCK and 293T cells12. Inﬂuenza A/
PR/8/1934 (H1N1), seasonal inﬂuenza B/Beijinghaidian/1386/
2013 (Victoria) and inﬂuenza B/Massachusetts/02/2012 (Yama-
gata) were propagated in embryonated chicken eggs according to
classical virological techniques. Virus titers were determined onMDCK cells and represented as the median tissue culture infective
dose (TCID50), as previously described
13. These viruses were
provided kindly by Dr. Yuelong Shu at China CDC.
2.2. Reagents and plasmids
Coelenterazine-h was purchased from Promega. Nucleozin and
TPCK-treated trypsin were obtained from Sigma. The Microsource
Library (2000 compounds) was obtained from commercial sources
and compounds from this library were dissolved in DMSO at
2 mmol/L. Plasmid pHH-Gluc (a kind gift from Dr. Erik de Vries8)
was used as template for Gluc reporter system (containing the
RNA polymerase I promoter/terminator and inﬂuenza A/WSN/33
NP segment UTRs) ampliﬁcation. The primers used are as follows:
forward primer 50–TATGAATTCGGAAAAACGCCAGC AAC-
30 and reverse primer 50–ATAAGGGCCCAAAATCTTCTTT-
CATCCGC-30. PCR products were cloned into pLenti6/V5-DEST
vector (Invitrogen) generating pLenti6-Gluc.
2.3. Establishing a stable reporter cell line
293T cells were transfected with pLenti6-Gluc using lipofecta-
mine2000 in accordance with the manufacturer's protocol, and
then were selected with 10 μg/mL Blasticidin 24 h post-
transfection. Under antibiotic selective pressure several clonal
colonies were obtained and tested for luciferase expression. One
clonal cell line demonstrated high-level expression of luciferase;
this cell line was named 293T-Gluc and was used for subsequent
experiments.
2.4. Gluc reporter assay
293T-Gluc cells were cultured to 90% conﬂuence, released with
0.25% trypsin-EDTA and resuspended in DMEM with 10% FBS
at 7 105 cells/mL. Cells were then seeded in the wells of 96-well
plate at 100 μL/well. After an overnight incubation at 37 1C and
5% CO2, cells were infected with the indicated inﬂuenza viruses,
which were contained in 10 μL serum-free DMEM culture
medium. Post-infection medium also contained TPCK-treated
trypsin with the ﬁnal concentration of 1 μg/mL.
In speciﬁcity studies, infection was allowed to proceed for 24 h
at 35 1C. For inﬂuenza A/PR/8/1934, inﬂuenza B/Beijinghaidian/
1386/2013 (Victoria) and inﬂuenza B/Massachusetts/02/2012
(Yamagata), infections were carried out at a multiplicity of 0.1,
1 and 10, respectively, whereas a multiplicity of 0.1 and 1 was
used when testing the response of inﬂuenza A/WSN/33 virus to
Gluc reporter assay.
The dynamic signal range of the Gluc reporter assay was
assessed by infecting 293T-Gluc cells with varying quantities of
inﬂuenza A/WSN/33 virus (MOI of 0.0001, 0.001, 0.01, 0.1 and 1)
and determining Gluc activity at various times post-infection (12,
24, 36 and 48 h post-infection).
For evaluation assay of antivirals and high-throughput screen-
ing, 1 μL of each tested compound was added to cells and
incubated for 2 h prior to infection, after which cells were infected
with inﬂuenza A/WSN/33 virus at an MOI of 0.05. After a further
incubation for 24 h at 37 1C, the cell supernatant was collected and
measured for Gluc activity. In each 96-well plate ribavirin and
DMSO were used as positive and negative controls, respectively.
The inhibition rate of the tested compounds was calculated with
the following equation, where RLU indicates relative light unit:
Figure 2 Speciﬁcity of Gluc reporter assay. Experiments were
conducted as described in Materials and Methods. 293T-Gluc cells
were seeded and infected with indicated viruses at various doses for
24 h. Infection with A/WSN/33 at an MOI of 10 was not tested. Gluc
activity of mock-infected cells was regarded as background and
indicated by a dashed line. Data were shown as average7standard
deviation (n¼3).
An assay for screening anti-IAV drugs 303Inhibition rate¼ (RLUinfected cellsRLUtested compound)/(RLUinfected cells
RLUmock-infected cells) 100%.
2.5. Luciferase activity assay
A stock of coelenterazine-h was prepared in ethanol to a concentration
of 1.022 mmol/L and stored at –20 1C. Before assay the stock was
diluted into PBS by a factor of 60, which was used as working
solution for luminescence. The working solution was held for 30 min
at room temperature in the dark to stabilize it14. For luminescence
analysis, 60 μL of working solution was added to 10 μL of cell-free
conditioned medium and measured for 0.5 s using a 96-well micro-
plate luminometer with automated substrate injection (Berthold Centro
LB 960). The results were expressed in relative light units (RLUs).
3. Results and discussions
3.1. Speciﬁcity for inﬂuenza A virus
In construction of pLenti6-Gluc, the open reading frame (ORF) of
the inﬂuenza A/WSN/33 NP protein was replaced by Gaussia
luciferase and this RNA segment was inserted in a human RNA
polymerase I promoter/terminator cassette in the reverse orienta-
tion and complementary sense. As a stable cell line, 293T-Gluc
cells that contain pLenti6-Gluc synthesize a viral negative strand
RNA constitutively, which expresses Gluc under control of the
untranslated regions (UTRs) of the inﬂuenza A/WSN/33 NP
segment (Fig. 1). We assessed the response of this reporter cell
line to different strains of inﬂuenza virus. As shown in Fig. 2, the
infection with inﬂuenza A viruses induced much higher luciferase
activity than did the two strains of inﬂuenza B virus. The
observation that the 293T-Gluc cell line is more responsive to
inﬂuenza A virus may reﬂect species speciﬁcity of UTR region for
the corresponding RdRp, which is consistent with a previous
observation7. Among all the virus strains tested, the A/WSN/33
strain exhibited the most potent ability to induce luciferase activity
when the cells were infected at identical MOI. Therefore, inﬂuenza
A/WSN/33 virus was used for all subsequent experiments.
3.2. Dynamic signal range of the 293T-Gluc reporter assay
To further optimize the assay a signal range was determined using
serial 10-fold dilutions of inﬂuenza A/WSN/33 virus. As shownFigure 1 Schematic of the inﬂuenza virus Gluc reporter construct. The
orientation and complementary sense between the inﬂuenza virus untransla
ﬂanked by a human RNA polymerase I (Pol I) promoter and terminator. Th
an inﬂuenza virus genome segment. Upon infection, the inﬂuenza virus poly
expressed. A eukaryotic selection marker of Blasticidin was used to estabin Fig. 3, infection at MOIs of 0.1 or higher induced a Gluc signal
at 12 h post-infection, and signal intensity signiﬁcantly increased
thereafter and reached a peak at 36 h post-infection. When infected
with virus at MOIs of 0.001 or lower, cells failed to generate a
detectable Gluc signal. It should be noted that viral infection at
an MOI of 1 induced signiﬁcant CPE in 293T-Gluc cells like
MDCK, while the cells kept a normal morphology during the
96 h time period of post-infection when the MOI was less than 0.1
(data not shown). This may explain the observation that the Gluc
signal from the cells infected at an MOI of 1 was less than that of
MOI of 0.1 (Fig. 3), most likely due to reduced cell viability.
Based on this result, the amount of virus used and the measure-
ment time point were set at an MOI of 0.05 and 24 h post-
infection, respectively.Gaussia luciferase open reading frame was inserted in the reverse
ted regions (UTRs) which serve as the viral promoter. This cassette is
e transcribed RNA is a vRNA-like negative sense RNA, which mimics
merase recognizes the UTRs and Gaussia luciferase is transcribed and
lish stable cell line 293T-Gluc.
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To ascertain assay sensitivity, three reference compounds, includ-
ing ribavirin, amantadine hydrochloride and nucleozin, were
examined in our assay. Ribavirin is used against several DNA
and RNA viruses including inﬂuenza viruses15,16. It is converted to
ribavirin monophosphate, which disturbs GTP synthesis, leading
to inhibition of RNA synthesis in cells17. Amantadine hydro-
chloride, approved for the treatment of inﬂuenza infections, acts in
the early phase of the life cycle of inﬂuenza A virus to target the
M2 ion channel18,19. Nucleozin is a novel inhibitor with anti-
inﬂuenza activity. It impedes inﬂuenza A virus replication by
triggering the aggregation of NP and inhibits its nuclear accumula-
tion20. We used the Gluc reporter assay to evaluate these antivirals
in dose-response experiments, measuring IC50 (Fig. 4). All the
compounds showed the ability to reduce the luciferase signal
driven by inﬂuenza A/WSN/33 virus. IC50 values determined from
our experiments were comparable to data previously reported
(Table 1), demonstrating the applicability of the Gluc reporter
assay for screening inﬂuenza inhibitors. Furthermore, compared
with the conventional plaque reduction assay (PRA)24, the method
herein is more rapid and simple for the determination of IC50
values. At least 48 h were needed before the number of plaques
could be calculated, whereas our assay can give results in 24 h
after infection. Moreover, this unbiased and automated method ofFigure 3 Signal range of the 293T-Gluc reporter assay. 293T-Gluc
cells were infected with varying quantities of inﬂuenza A/WSN/33
virus. Infections were performed at MOI of 0.0001, 0.001, 0.01, 0.1
and 1. Gluc activities were measured at 4 times points with equal
intervals of 12 h and that of mock-infected cells was regarded as
background (indicated by a dashed line, which is very approachable to
X-axis). Data are shown as average7standard deviation (n¼3).
Figure 4 Dose–response relationships of three anti-inﬂuenza inhibitors.
compounds were dissolved in DMSO at various concentrations. Data from
Three independent experiments were done, and representative data are shoinfectivity quantitation avoids tedious plaque counting, making it
an ideal approach.3.4. High-throughput screening
The above results suggest the potential to use the Gluc reporter
assay to screen compounds against inﬂuenza A virus. To ensure
that the assay can be used in high-throughput screening, we
assessed its accuracy by using several statistical parameters25
(Table 2). Z0 factor is a simple statistical characteristic for HTS
assay. It can be used to evaluate the performance of an assay. A
robust assay should have a Z0 factor40.5 and the larger the value
of Z0 factor, the better the data quality of the assay26. The Z0 factor
in our experiments was 0.84 (n¼48), which is considered to be
excellent for use in HTS (Fig. 5). Normally, infected cells treated
with a positive anti-inﬂuenza compound are used as positive
control for calculating the Z0 factor. Nevertheless, according to the
assay validation guidance for agonist assays (http://www.ncbi.nlm.
nih.gov/books/NBK83783/), the background signal is also suitable
for use as a ‘minimum signal’. Since viral infection acts as an
agonist of luminescent protein, we used mock-infected cells as
positive control in the validation analysis. Similarly, other work
used mock-infected cells as positive control to calculate the Z0
factor27. In addition, as shown in Fig. 4, most of the anti-inﬂuenza
compounds tested were able to achieve full inhibition in our assay.
Moreover, the minimum signals derived from infected cells treated
with one of the positive anti-inﬂuenza compounds were close to
that of mock-infected cells.
CV is another parameter used for quality assessment. It reﬂects
signal deviation within an assay and is recommended to be less than(A) Ribavirin; (B) amantadine hydrochloride; (C) nucleozin. Tested
the assay were analyzed and calculated by GraphPad Prism software.
wn as average7standard deviation (n¼3).












Nucleozin 0.2370.04 0.32 23
aActivity against inﬂuenza A/WSN/33 virus.
bValues are mean7standard deviation from three independent
experiments.
Table 2 Summary of statistical parameters to assess the






aZ0 ¼1–3(STDinfected cellsþSTDmock-infected cells)/(MEANinfected cells
MEANmock-infected cells).
b%CV (coefﬁcient of variation)¼STDinfected cells/MEANinfected cells
 100%.
cS/B (signal-to-background ratio)¼Meaninfected cells/Meanmock-
infected cells.
dS/N (signal-to-noise ratio)¼ (Meaninfected cellsMeanmock-infected
cells)/((STDinfected cells)
2þ(STDmock-infected cells)2)1/2.
Figure 5 Determination of Z0 factor of the 293T-Gluc report assay.
Approximately 7 104 293T-Gluc cells were seeded per well of a 96-
well tissue culture plate and half were infected with inﬂuenza A/WSN/
33 virus at an MOI of 0.05. At 24 h post-infection, Gluc activity was
measured and Z0 factor value was calculated as described.
Figure 6 Results of the pilot high-throughput screening. Two thousand
compounds from Microsource library were automatically added to cells
by machine arm and ﬁnal concentrations were 20 μmol/L. Each circle
represents the inhibition rate of each compound. Seventeen compounds
showed 90–100% inhibition of luminescence signal with a hit rate
of 0.85%.
An assay for screening anti-IAV drugs 305or equal to 20% (http://www.ncbi.nlm.nih.gov/books/NBK83783/).
The CV of our assay was 5.79%, which meets the requirements for
HTS. In addition, the S/B ratio (23.24) and the S/N ratio (16.29) were
comparable to those of other HTS assays reported28,29, proving our
assay was suitable for use in a high-throughput screen.
As a proof of concept, we carried out a pilot screening of the
Microsource Library as described above and the results are plotted
in Fig. 6. In each 96-well plate, ribavirin and DMSO were used as
a positive and negative control, respectively. Majority of the 2000
screened compounds did not decrease the luminescence signal by
more than 50%. Seventeen showed strong luminescence reduction
by 90%–100%, which translates to a hit rate of 0.85%. Compared
with assays exploiting the principle of cytopathic effects (CPE)
protection30, the approach established here is rapid and simple for
anti-inﬂuenza inhibitor screening. We anticipate that this approach
will facilitate the discovery of compounds with anti-inﬂuenza
activity and lead to drug development.4. Conclusions
Inﬂuenza virus remains a health threat, and much more work needs
to be done to discover new antivirals. In this work we reported a
cell-based high-throughput assay to identify inhibitors for inﬂuenza
virus. The assay used Gaussia luciferase as a readout. Severalcriterions for HTS were evaluated, including Z0 factor and CV.
Results obtained validated the robustness of our assay. Furthermore,
we used this high-throughput assay to screen 2000 small molecules
at 20 μmol/L. Seventeen compounds showed 90%–100% inhibition
of luminescence signal for a rate of 0.85%. Utilization of this cell-
based high-throughput assay will beneﬁt identiﬁcation of new anti-
inﬂuenza lead compounds in future work.
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